Amgen - AMGN Stock Forecast, Price & News

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Analyst Ratings Changes

A number of analysts have issued reports on AMGN shares. Oppenheimer reissued a "buy" rating and issued a $290.00 price objective on shares of Amgen in a report on Wednesday, August 10th. TheStreet raised shares of Amgen from a "c+" rating to a "b" rating in a report on Monday. Atlantic Securities cut their price target on shares of Amgen from $190.00 to $182.00 and set an "underweight" rating for the company in a report on Tuesday, August 9th. StockNews.com downgraded shares of Amgen from a "strong-buy" rating to a "buy" rating in a report on Monday, August 8th. Finally, Piper Sandler upped their price target on shares of Amgen from $260.00 to $265.00 and gave the stock an "overweight" rating in a report on Friday, August 5th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, Amgen presently has a consensus rating of "Hold" and an average target price of $245.14.

Amgen Price Performance

AMGN opened at $249.70 on Friday. The company has a market capitalization of $133.57 billion, a price-to-earnings ratio of 21.16, a PEG ratio of 2.05 and a beta of 0.56. The company has a quick ratio of 1.17, a current ratio of 1.53 and a debt-to-equity ratio of 14.76. The firm has a 50-day moving average price of $245.29 and a 200-day moving average price of $241.27. Amgen has a twelve month low of $198.64 and a twelve month high of $258.45.

Amgen (NASDAQ:AMGN - Get Rating) last posted its earnings results on Thursday, August 4th. The medical research company reported $4.65 earnings per share for the quarter, topping the consensus estimate of $4.40 by $0.25. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.53 billion. Amgen had a net margin of 24.92% and a return on equity of 218.34%. The company's revenue was up 1.0% on a year-over-year basis. During the same quarter last year, the company earned $4.38 earnings per share. Equities analysts expect that Amgen will post 17.42 EPS for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 8th. Stockholders of record on Thursday, August 18th will be paid a $1.94 dividend. The ex-dividend date of this dividend is Wednesday, August 17th. This represents a $7.76 annualized dividend and a dividend yield of 3.11%. Amgen's payout ratio is 65.76%.

Insider Transactions at Amgen

In other news, Director R Sanders Williams sold 600 shares of the firm's stock in a transaction that occurred on Monday, May 23rd. The shares were sold at an average price of $250.00, for a total value of $150,000.00. Following the completion of the transaction, the director now directly owns 5,501 shares in the company, valued at $1,375,250. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.46% of the company's stock.